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Abstract
Background: Erythroid nuclear cells (ENC) of the bone marrow (BM) have not previously been
considered as important producers of wide spectrum of haemo- and immunoregulatory cytokines.
The aim of the current work was to confirm the production of the main hemo- and
immunoregulatory cytokines in human ENC from BM.
Results: We used native human BM ENC in our experiments. We for the first time have shown,
that the unstimulated erythroblasts (Gl A+  or AG-EB+) produced a wide spectrum of
immunoregulatory cytokines. Human BM ENC produce cytokines such as interleukn (IL)-1β, IL-2,
IL-4, IL-6, interferon (IFN)-γ, transforming growth factor (TGF)-β1, tumor necrosis factor (TNF)-
α and IL-10. They can be sub-divided into glycophorin A positive (Gl A+) and erythroblast antigen
positive (AG-EB+) cells. To study potential differences in cytokine expression between these
subsets, ENC were isolated and purified using specific antibodies to Gl A and AG-EB and the
separated cells were cultivated for 24 hours. The cytokine contents of the supernatant were
measured by electrochemiluminescence immunoassay. Quantitative differences in TGF-β1 and
TNF-α production were found between Gl A+ and AG-EB+ BM ENC. Furthermore, in vitro
addition of erythropoietin (EPO) reduced IFN-γ and IL-2 production specifically by the AG-EB+
ENC. Thus, Gl A+ and AG-EB+ ENC produce IL-1β, IL-2, IL-4, IL-6, IFN-γ, TGF-β1 and TNF-α. Gl
A+ ENC also produce IL-10.
Conclusion: Cytokine production by erythroid nuclear cells suggests that these cells might be
involved in regulating the proliferation and differentiation of hematopoietic and immunocompetent
cells in human BM.
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Background
Haematopoesis is regulated by lymphoid and non-lym-
phoid cells through a complex network of paracrine and
autocrine mechanisms involving cytokines, growth fac-
tors and their receptors. However, although stromal [1-6],
endothelial [7-10], megakaryocytic [11,12] and osteo-
genic cells [13-16] and lymphocytes are known to express
cytokines, erythroid nuclear cells (ENC), the major cell
population of the BM, are not considered as important
producers of hemo- and immunoregulatory cytokines.
Experiments on ENC isolated from mouse spleen under-
going erythroid hyperplasia, and on cells separated from
single erythroid colonies, have revealed that mRNAs for
cytokines such as IL-1α, IL-1β, IL-4, IL-6, granulocyte-
macrophage colony stimulating factor (GM-CSF), TGF-β1
and IFN-γ are present [17,18]. Production of GM-CSF and
IFN-γ has also been reported [17]. Similarly, IL-2 and IL-3
mRNAs were found after erythroid cells were treated with
erythropoietin (EPO) [17-20]. Human fetal liver eryth-
roid cells have also been shown to produce such cytokines
as IL-1, IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ and TGF-β1
[20]. Stopka and co-authors have demonstrated the ability
of burst-forming unit erythroid cells (BFU-E) to express
and produce EPO [21]. Also it has been shown that eryth-
roid cells express and produce vascular-endothelial
growth factor (VEGF)-A and placental growth factor
(PlGF) both in vitro and in vivo. Production of these pro-
teins varies during differentiation and is increased 100-
fold by PlGF and 3-fold by VEGF-A [22]. Macrophage col-
ony stimulating factor (M-CSF), fibroblast growth factor
(FGF)-2, VEGF-A, hepatocyte (H)GF, insulin-like (I)GF-1,
IL-1β, trombopoietin (TPO), TNF-α, IFN-γ, FAS-L, and
macrophage inflammatory protein (MIP)-1α mRNAs are
also expressed in BFU-E isolated from BM, and VEGF-A
and TGF-β1 are produced [23,24]. All these data allow us
to consider erythroid cells as cytokine producers involved
in regulating hemo- and immunopoiesis.
The aim of the current work was to confirm previous
observations by studying the production of the main
hemo- and immunoregulatory cytokines, IL-1β, IL-2, IL-4,
IL-6, IL-10, TNF-α, IFN-γ and TGF-β1, in human ENC
from BM. Furthermore, we wished to determine whether
different subsets of ENC (AG-EB+ and Gl A+ erythroid
cells from human BM) might account for altered expres-
sion levels. Expression of both these markers is specific to
erythroid cells; they are absent from the membranes of
other blood-forming cells. AG-EB is expressed in a propor-
tion of BFU-E cells (up to 4% of AG-EB+ BFU-E cells) and
on colony-forming units – erythroid (CFU-E) (up to 36%
of AG-EB+ CFU-E cells) [25]. Its expression on erythrob-
lasts is further increased (up to 90% in AG-EB+erythrob-
lasts). Later in development, AG-EB expression decreases,
and only 4% of reticulocytes carry AG-EB [25]. In contrast,
Gl A is expressed in a minor subpopulation of the CFU-E
cells (less than 4%). On the erythroblasts this expression
is increased and reach up to 100% in reticulocytes [26,27].
Sheme of AG-EB and Gl A expression during erythroid
maturation present in Table 1.
In this article we show which human BM ENC produce
the cytokines IL-1β, IL-2, IL-4, IL-6, IFN-γ, TGF-β1, TNF-α
and IL-10.
Results
Erythroid cells were separated according to the presence of
the surface markers AG-EB and Gl A. BM erythroid cells
carrying AG-EB produce the cytokines IL-1β, IL-2, IL-4,
TNF-α, IFN-γ and TGF-β1 (figure 1). Those carrying Gl A
also produce these cytokines and in addition might be
secrete IL-10 (figure 1). Interestingly, erythroid cells carry-
ing AG-EB release more TGF-β1 (p < 0.05) than Gl A+ cells,
whereas Gl A+ secrete more TNF-α (p < 0.05).
To the best of our knowledge, this difference between BM
AG-EB+ and Gl A+ ENC has not previously been reported.
To verify that the cytokines were truly expressed by these
erythroid cells, we isolated erythoid colonies by cultivat-
ing single BM cells in MethoCult H4433 medium. As
shown in Table 2, the cytokines produced were compara-
ble between ENC derived from erythroid colonies and
ENC enriched from the BM.
Table 1: Expression of AG-EB and Gl A during erythroid maturation. The percentage of positive cells detected by flow cytometric 
analysis [25, 26, 27].
% of positive cells
BFU-E CFU-E Proerythroblasts → erythroblasts reticulocytes
AG-EB 0 – 4 36 93–95 4
Gl A 0 0 – 4 Increase with maturation 100BMC Cell Biology 2004, 5:39 http://www.biomedcentral.com/1471-2121/5/39
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EPO regulates the proliferation and differentiation of
erythroid cells [28-30]. Therefore, we assessed the effect of
EPO on our different ENC cell populations and found
that the production of some hemo- and immunoregula-
tory molecules was altered (figure 2). For instance, EPO
treatment of AG-EB+ cells led to a 99% decrease in IFN-γ
production and a 50% decrease in IL-2 production, and
the production of IL-1β and TNF-α was enhanced. How-
ever, EPO treatment had no discernible effect on the
cytokine profile of Gl A+ cells.
Discussion
We have shown that the native BM ENC can produce a
wide spectrum of cytokines, which are capable of both
stimulating and inhibiting erythropoiesis. Cytokine
production has been confirmed using ENC isolated from
erythroid colonies cloned from a single BM cell.
Earlier we demonstrated cytokine production by ENC
derived from fetal tissues [19,20]. However, there was a
great difference between the profiles of cytokines released
by BM and fetal ENC.
TGF-β1 is known to inhibit the proliferation of erythroid
precursors and to provoke or accelerate the terminal dif-
ferentiation of mature erythroid cells [31-33]. The fetal
AG-EB+ and Gl A+ erythroid cells produced TGF-β1 in con-
centrations less than 5 pg/ml and we suggested that this
could be related to the increased proliferative activity of
erythroid cells in the fetal liver [20]. We propose that the
high level of TGF-β1 production by BM erythroid cells is
probably related to the need to restrain erythroid cell pro-
liferation in healthy adult individuals. This hypothesis
were declared also in review [24].
It is notable that BM erythroid cells produce not only
inhibitors but also high levels of stimulators of erythro-
poiesis such as IL-4 and IL-6, especially in the presence of
EPO [34,35]. The production of these hemoregulatory
molecules suggests that erythroid cells have a capacity for
self-regulation. Interestingly, IL-2, which inhibits erythro-
Cytokine production by BM erythroid nuclear cells carrying  Erythroblast Antigen and Glycophorin A Figure 1
Cytokine production by BM erythroid nuclear cells 
carrying Erythroblast Antigen and Glycophorin A.  
– BM AG-EB+ erythroid nuclear cells; ■  – BM Gl A+ eryth-
roid nuclear cells. All populations were cultivated for 24 h at 
concentrations of 106 cells per ml. Results present as (Mean 
± SEM). n/d – not detected. * – P < 0.05.
Table 2: Concentration of cytokines in conditioned medium 
derived from erythroid cells. Concentration of cytokines (pg/ml) 
in conditioned medium derived from enriched population of BM 
erythroid cells (1 × 106/ml) and erythroid cells isolated from 
erythroid colonies (1 × 106/ml). Results were obtained from at 
least three independent experiments (Mean ± SEM).
Enriched erythroid 
nuclear cell population
Erythroid nuclear cells derived 
from erythroid colonies
IL-1β 78.64 ± 44.84 10.8 ± 0.39
IL-2 255.36 ± 88 237.73 ± 237.73
IL-4 62.66 ± 45.28 738.26 ± 640.15
IL-6 741.08 ± 395.95 324 ± 56.14
IL-10 121.26 ± 53.22 73.4 ± 73.4
TNF-α 2.59 ± 1.41 0.0
IFN-γ 766.35 ± 319.45 752.88 ± 492.65
TGF-β1 524.88 ± 372.59 479.25 ± 267.75
Influence of EPO on cytokine production by BM AG- EB+erythroid nuclear cells Figure 2
Influence of EPO on cytokine production by BM AG-
EB+erythroid nuclear cells.  – BM AG-EB+ erythroid 
nuclear cells; ■  – BM AG-EB+ erythroid nuclear cells after 
treatment with EPO. BM AG-EB+ erythroid nuclear cells (106 
cells/ml) were treated with EPO (2 U/ml) for 24 h. Results 
present as (Mean ± SEM). n/d – not detected. * – P < 0.05.BMC Cell Biology 2004, 5:39 http://www.biomedcentral.com/1471-2121/5/39
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poiesis [36], is produced by these cells in smaller quanti-
ties or, like IL-10, is not produced at all.
Besides the differences in production of some cytokines
by BM erythroid cells, there are parallels with cytokine
production from fetal erythroid cells. A similar situation
can be observed when TNF-α production by BM erythroid
cells is compared with those from fetal liver [20]. In both
cases AG-EB+ cells produce significantly less TNF-α than
Gl A+ (figure 1). TNF-α is a known inhibitor of precursor
cell proliferation and an inducer of cell death in a propor-
tion of these cells [37,38]. Therefore it is plausible that
erythroid cells use this cytokine for autocrine self-regula-
tion, by maintaining a negative feedback loop. If this is so,
then relatively small increases in the number of more dif-
ferentiated Gl A+ cells would lead to a decreased precursor
proliferation rate, due to the elevated level of TNF-α. Neg-
ative feedback can also be maintained through IFN-γ,
which is produced at the same level by both Gl A+ and AG-
EB+ cells. However, IFN-γ initiates apoptosis only in BFU-
E [39,40], while in CFU-E cells it increases the expression
of Bcl-x and protects these cells from elimination. Thus,
IFN-γ enhances the differentiation of erythroid precursors
[41,42]. We found no statistical significant differences
between AG-EB+ and Gl A+ cells in the production of IL-
1β, IL-2, IL-4, IL-6 and IL-10.
The capacity of erythroid cells to change their cytokine
expression profiles quantitatively and qualitatively under
different conditions is an important indicator of their
active role in the regulation of hemo- and immunopoie-
sis. Similar data were previously obtained in mouse cells
and are presented here for human BM erythroid cells.
Treatment with EPO leads to significant changes in IL-2
and IFN-γ production. Notably, IFN-γ and IL-2 secretion
by AG-EB+ cells is lowered in the presence of EPO, while
Gl A+ cells show no such change. This difference could be
related to EPO-R expression in AG-EB+ cells, which are
mainly CFU-E and erythroblasts [43-45]. Expression of
this receptor ceases in more differentiated early erythrob-
lasts. Indeed, Gl A+ cells do not express EPO-R, since late
erythroblasts and more differentiated forms of erythroid
cells are prevalent in this population [28,43,46]. The EPO-
induced changes in cytokine production mainly concern
inhibitors of erythroid precursor proliferation, such as IL-
2 and IFN-γ. Thus, one mechanism by which erythroid cell
proliferation is stimulated could be a decrease in prolifer-
ation inhibitor production by these cells as a result of EPO
treatment.
Conclusion
Erythroid nuclear cells appear to be active producers of
hemo- and immunoregulatory cytokines, involved in reg-
ulating the proliferation and differentiation of hemat-
opoietic and immunocompetent cells in human BM.
Changes in the cytokines produced by erythroid cells in
response to EPO suggests the ability of these cells to




This work was approved by the local ethics committee.
After obtaining informed consent, sternum BM samples
were collected from 8 normal healthy volunteers. All sam-
ples used in this study exhibited normal myelograms. The
enriched population of erythroid cells was isolated from
BM mononuclear cells by depleting of adherent cells and
granulocytes as described previously [19].
Isolation of erythroid cell population carrying a surface 
erythroid antigen and Glycophorin A
We used indirect panning to obtain cells expressing either
the erythroid antigen (AG-EB) or Glycophorin A (Gl A)
[19]. Monoclonal mouse anti-red blood cell Glycophorin
A (MAS518, Harlan-Sera Lab, England), and monoclonal
HAE-9 antibodies against AG-EB (kindly provided by
Prof. Mechetner, Russia) were used [25]. Affinity isolated
polyclonal rabbit anti-mouse immunoglobulin (Biosan,
Russia) was used as a secondary reagent to coat Petri
dishes during the panning procedure. To avoid non-spe-
cific binding to FcRs, cells were blocked with aggregated
normal human IgG and then incubated with anti-Gl A or
HAE-9 antibodies for 50 min at 4°C. Cells were trans-
ferred to Petri dishes covered with rabbit anti-mouse anti-
bodies for panning for 50 min at 4°C. Subsequently,
immobilised cells were collected, cultivated for 24 h in
RPMI-1640 with 10% horse serum (Sigma, USA) with and
without EPO [19,47]. Samples were collected after
cultivation.
Cultivation of erythroid cells with EPO
1 × 106 cells were placed in culture medium containing 2
U/ml Epo (Boehringer Mannheim, Germany) for a 24-h
incubation.
CFU-E
Cells from the enriched erythroid population were main-
tained as described above [19,20] at 2·105/ml and then
cultivated in MethoCult H4433 medium (Stemcell Tech.
Inc. Vancouver, B.C.) for 14 days. Colonies were visually
characterised as CFU-E using an inverted microscope.
After cultivation, the colonies were harvested and washed
twice to remove methyl cellulose. The resulting cellular
suspension (1 × 106/ml) was cultivated for 24 h in RPMI-
1640 with 10% horse serum, then supernatants were col-
lected. Samples were stored at -20°C.BMC Cell Biology 2004, 5:39 http://www.biomedcentral.com/1471-2121/5/39
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Cells purity
Cell purity was assessed using Nocht-Maksimov staining
of smears [48] and staining of haemoglobin with benzi-
din [49]. All cells (Gl A+, AG-EB+ and CFU-E cells) were
characterised as erythroblasts and were haemoglobin
positive.
Electrochemiluminescence (ECL) method for quantitative 
determination of cytokines
Quantitative determination of cytokines was performed
by the electrochemiluminescent immunoassay [50-52]
using an ORIGEN Analyzer (IGEN Inc., USA) according to
the manufacturer's protocol. Calibration curves ranged
from 10 to 10,000 pg/ml. Assay sensitivity was 2.8 pg/ml,
2 pg/ml, 2 pg/ml and 6 pg/ml for IL-1β, IL-2, IL-4 and IL-
6, respectively. Assay sensitivities were 2 pg/ml, 1 pg/ml,
1 pg/ml and 2 pg/ml for IL-10, TNF-α, IFN-γ, and TGF-β1,
respectively. The ruthenylated and biotinylated antibod-
ies were diluted to working concentrations (µg/ml) 1:1,
1:1, 1:2 and 2:1 for IL-1β, IL-2, IL-4 and IL-6, respectively.
The biotinylated and ruthenylated antibodies were
diluted to working concentrations (µg/ml) 2:2, 1:1, 2:1
and 4:2 for IL-10, TNF-α, IFN-γ and TGF-β1, respectively.
For TGF-β1 detection, samples were treated with HCl to
obtain intact and easily detectable proteins as described
[53].
Antibodies
All polyclonal and monoclonal antibodies were pur-
chased from R&D Systems (Abington, UK). The following
antibodies were used: against recombinant IL-1β, IL-2, IL-
4, IL-6, IL-10, TNF-α, IFN-γ, TGF-β1 polyclonal and mon-
oclonal: anti-hIL-1β #AB-201-NA, anti-hIL-1β #MAB201,
anti-hIL-2 #AB-202-NA, anti-hIL-2 #MAB202, anti-hIL-4
#AB-204-NA, anti-hIL-4 #MAB204, anti-hIL-6 #AB-206-
NA, anti-hIL-6 #MAB206, anti-hIL-10 #AB-217-NA, anti-
hIL-10 #MAB217, anti-hTNF-α #AB-210-NA, anti-hTNF-α
#MAB210, anti-hIFN-γ #AB-285-NA, anti-hIFN-γ
#MAB285, anti-hTGF-β1 #AF-101-NA, anti-hTGF-β1
#MAB240. No antibody used displayed cross-reactivity
with other cytokines.
Cytokines
Recombinant cytokines were purchased from R&D Sys-
tems (Abington, UK): rhIL-1β #201-IL, rhIL-2 #202-IL,
rhIL-4 #204-IL, rhIL-6 #206-IL, rhTNF-α #210-TA, rhIFN-
γ #285-IF, rhTGF-β1 #240-B-002; and PeproTech, Inc.
(Rocky Hill, NJ): rhIL-10 #200-10 was used for calibration
curves. All the recombinant cytokines were diluted to 2
µg/ml in PBS, pH 7.4, supplemented with 0.05% NaN3
and 0.1% BSA (aliquots were kept at -70°C before use).
Statistical analysis
Results are presented as means ± SEM. Statistical signifi-
cance was determined using the nonparametric Mann-
Whitney U-test. P < 0.05 was considered to be significant.
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